Savant Capital, LLC Esperion Therapeutics, Inc. Transaction History
Savant Capital, LLC
- $17.8 Billion
- Q3 2025
A detailed history of Savant Capital, LLC transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Savant Capital, LLC holds 43,956 shares of ESPR stock, worth $127,472. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43,956
Previous 21,876
100.93%
Holding current value
$127,472
Previous $21,000
452.38%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ESPR
# of Institutions
215Shares Held
114MCall Options Held
643KPut Options Held
769K-
Black Rock Inc. New York, NY14MShares$40.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.1MShares$35.1 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY9.75MShares$28.3 Million0.51% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT7.06MShares$20.5 Million0.1% of portfolio
-
Pender Fund Capital Management Ltd. Vancouver, A16.68MShares$19.4 Million7.68% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $193M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...